openPR Logo
Press release

Peripheral Artery Disease Market Size Worth USD 3.47 billion by 2023 | Top Companies are Bayer HealthCare Pharmaceuticals (Germany), TheraVasc Inc. (US), Abbott Laboratories (U.S), AstraZeneca Plc. (UK), Johnson & Johnson (U.S)

Peripheral Artery Disease Market

Peripheral Artery Disease Market

Market Scenario

Following a careful analysis of the global peripheral artery disease market, Market Research Future (MRFR) concludes that it will reach the valuation of USD 3.47 billion by 2023. The market is set to rise from its previous value of USD 2.23 billion in 2016, at a CAGR of 6.5% during the forecast period (2017-2023).

Growth Factors and Key Restraints

Rise in Geriatric Population

There has been a dramatic surge in the number of aging people worldwide. As per a WHO report, at least 524 million people were above the age of 65 in the year 2010, and the prediction is that number will be reaching 1.5 billion by 2050. This figure is expected to constitute almost 16% of the total global population. Furthermore, the number of elderly individuals is directly proportional to the number of disorders amongst them, like hypertension and diabetes, increasing the risk for peripheral artery disease. Thus, the expanding geriatric population will leave a positive impact on the growth of the global market in the years to come.

Get Free Sample copy of Report @ https://www.marketresearchfuture.com/sample_request/1540

Advanced Treatment Options

The peripheral artery disease market size is all set to expand significantly from 2017 to 2023, with a key reason being the increasing advanced treatment options as well as tools like atherectomy devices. These kinds of tools are used for debulking the plaque before using a stent for treatment. Thus, with the surging prevalence of calcified and hard lessions coupled with the upgraded atherectomy procedure, the overall growth of the market is going to be highly promising in the forthcoming years. Apart from this, other latest interventional products like drug eluting stents and drug coated balloon stents will also prove to be instrumental in the lucrative growth of the market during the conjectured time frame.

Increase in Research and Development Expenditure

Adding on to the list of growth drivers, one factor that will give a substantial boost to the market growth is the rising research and development expenditure. As per reports by European Federation of Pharmaceutical Industries and Association, in 2016, the R&D expenditure in the Pharmaceutical Industry was estimated at a whopping value of EUR 35000 million. Moreover, as per the Centers for Disease Control and Prevention, in 2015, the per capita national health expenditure was approximately USD 9,990, with the total national health expenditure being USD 3.2 trillion. Also, few reports suggest that out of total national health expenditures in the United States (US), the prescription drugs accounted for 10.1% of the total share.

Get an Exclusive Discount on Report @ https://www.marketresearchfuture.com/check-discount/1540

Rising Trends in Peripheral Artery Disease Market

At present, the peripheral artery disease market is governed by numerous players. Also, as a result of the increasing research and development expenditure, a number of existing as well as new marketers are progressively developing advanced drugs that can control this specific condition.

For instance, Medtronic is one such company in the peripheral artery disease market, that is one of the largest standalone medical equipment development company in the world. The company boasts of a diverse portfolio of a range of products like NC Sprinter RX/ OTW Noncompliant Balloon Dilatation Catheter, NC Euphora Noncompliant Balloon Dilatation Catheter, Euphora Semicompliant Balloon Dilatation Catheter, among others.

Market Segmentation

The market for peripheral artery disease is segmented on the basis of devices, drugs and types of diseases.

The global peripheral artery disease market, by the types of devices, is segmented into stents, angioplasty balloon catheters, drug-eluting balloons, atherectomy devices and others. Stents is sub-segmented into balloon-expandable and self-expandable, whereas the atherectomy devices are sub-segmented into rotational, orbital, laser and directional.

The types of drugs used for treating peripheral artery disease include lipid-lowering drugs, blood pressure lowering drug, glucose regulating drug, clot preventing drug and others.

The types of diseases mentioned in the report are blood clotting disorders, lymphedema, atherosclerosis and others.

Get full report & TOC @: https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=1540

Regional Insight

The regional segments in the global peripheral artery disease market are Asia Pacific, Europe, North America, and the Middle East & Africa.

With the largest share in the global market, North America seems to be on an upward trajectory due to the increasing number of people suffering from major or minor peripheral diseases. Moreover, the increasing obese and diabetic patients in the region has accelerated the demand for the drugs needed for the treatment of peripheral artery diseases. Other factors working in favor of the regional market include the growing awareness regarding the disease, favorable reimbursement policies, as well as expanding geriatric population.

On the other side, the growing population in the Asia Pacific region coupled with the speedy rate of development is luring numerous manufacturers to the region. This will be a key reason for the lucrative growth rate of the regional market in the coming years. Apart from this, Asia Pacific also presents lucrative opportunities to the market, in the form of surging awareness among patients about the latest interventional treatment options.

The growth drivers of the peripheral artery disease market in Europe include the improved screening and detection of the disease, the rising geriatric population, and the continuous advancements in technology. Of course, the strikingly improving healthcare infrastructure and the healthcare industry has also been one of the most important factors in the market growth over the years.

The Middle East and Africa peripheral artery disease market will also be making somewhat similar strides as other regional markets, backed by the growing interest for minimally invasive strategies, evolving lifestyle, maturing population and the upsurge of peripheral artery diseases.

Key Vendors

Bayer HealthCare Pharmaceuticals (Germany), TheraVasc Inc. (US), Abbott Laboratories (U.S), AstraZeneca Plc. (UK), Boston Scientific Corporation (U.S), Johnson & Johnson (U.S), Medtronic (Ireland), Betagenon AB (Sweden), nGes MG, Inc. (Japan), Proteon Therapeutics, Inc. (US), Merck & Co., Inc. (US), Angioscore, Inc. (U.S), Symic Bio, Inc. (US), CardioVascular BioTherapeutics, Inc. (US), Bristol-Myers Squibb Company (US), Sanofi S.A. (France), are among some of the top players in the global peripheral artery disease market.

Get access to full summary @: https://www.marketresearchfuture.com/reports/peripheral-artery-disease-market-1540

Industry Developments

February 2019 - Mercy Hospital (US) is all set to offer a supervised exercise therapy program for those afflicted with symptomatic Peripheral Artery Disease (PAD). The 12-week supervised exercise therapy program will involve treadmill walking, along with various other exercise modalities, supervised by exercise physiologists, who will ensure the safety of patients.

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Peripheral Artery Disease Market Size Worth USD 3.47 billion by 2023 | Top Companies are Bayer HealthCare Pharmaceuticals (Germany), TheraVasc Inc. (US), Abbott Laboratories (U.S), AstraZeneca Plc. (UK), Johnson & Johnson (U.S) here

News-ID: 1688225 • Views:

More Releases from Market Research Future (MRFR)

Tofu Market to Reach USD 2.7 Billion by 2032 at 9.01% CAGR Driven by Rising Plant-Based Food Preferences
Tofu Market to Reach USD 2.7 Billion by 2032 at 9.01% CAGR Driven by Rising Plan …
The global tofu market is poised for substantial growth over the next decade, projected to reach an impressive valuation of USD 2.7 billion by 2032. This expansion reflects a compound annual growth rate (CAGR) of 9.01% from 2024 to 2032, fueled by a surge in consumer demand for plant-based foods and an evolving global food culture. As more consumers seek healthier and sustainable alternatives to animal-based protein sources, tofu has
Plant-Based Food Ingredients Market to Hit USD 40.2 Billion by 2035 at 7.96% CAGR Driven by Health & Sustainability
Plant-Based Food Ingredients Market to Hit USD 40.2 Billion by 2035 at 7.96% CAG …
The global plant-based food ingredients market is witnessing remarkable growth, propelled by an increasing shift in consumer preferences toward healthier and more sustainable food options. According to recent market research by Market Research Future, the market was valued at USD 16.03 billion in 2023 and is projected to reach an impressive USD 40.2 billion by 2035. This growth trajectory is expected to continue at a compound annual growth rate (CAGR)
Semolina Market to Reach USD 2.57 Billion by 2032 at 2.31% CAGR, Driven by Health Trends & Flour Mill Growth
Semolina Market to Reach USD 2.57 Billion by 2032 at 2.31% CAGR, Driven by Healt …
The global semolina market is poised for steady growth over the coming decade, with its valuation expected to reach USD 2.57 billion by 2032. According to the latest Market Research Future analysis, the market was valued at USD 2.12 billion in 2023 and is projected to expand from USD 2.14 billion in 2024 to USD 2.57 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 2.31% during the
Ginger Extract Market to Reach USD 2.18 Billion by 2034 at 5.4% CAGR Driven by Demand for Natural Ingredients
Ginger Extract Market to Reach USD 2.18 Billion by 2034 at 5.4% CAGR Driven by D …
The global ginger extract market is poised for substantial growth in the coming decade, with a projected valuation of USD 2.18 billion by 2034. According to the latest analysis from Market Research Future, the market was valued at USD 1.29 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2034. This robust growth trajectory is largely fueled by increasing

All 5 Releases


More Releases for Disease

Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research. Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight: Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and